摘要
目的观察糖尿病大鼠脑组织神经生长因子(NGF)mRNA表达变化及口服降糖药致低血糖的影响作用。方法64只Wistar大鼠分为对照组(16只)、糖尿病模型组(48只),制备高脂高糖饮食+腹腔注射链脲佐菌素致2型糖尿病大鼠模型,模型组分为非药物组(16只)、口服药物治疗组(16只)和低血糖组(16只),口服药物治疗组和低血糖组大鼠均予格列本脲+二甲双胍灌胃给药,低血糖组剂量为口服药物治疗组5倍,每天1次,连续12d,各组大鼠分别于低血糖反应第3、6、9、12天取脑组织行RT-PCR法NGF mRNA检测。结果与对照组相比,糖尿病模型组3组大鼠脑组织NGF mRNA表达均不同程度下降,低血糖降低最为显著(P<0.01),与非药物组比较,口服药物治疗组升高明显(P<0.01),低血糖组则进一步降低(P<0.01)。结论口服降糖药可有效增强糖尿病大鼠脑组织NGF mRNA表达,而口降糖药致低血糖能使NGF mRNA表达进一步下降,不利于糖尿病神经病变的修复。
Objective To observe the expression of NGF mRNA in rats brain with diabetes and the effects of hypoglycemia caused by oral antidiabetic drugs on NGF mRNA.Methods A total of 64 adult Wistar rats were randomly divided into control group（16）and diabetes model group（48）.Using high fat and high sugar diet＋intraperitoneal injection of streptozotocin to prepare type 2diabetes model.The diabetes model group was randomly divided into non-medication group（16）,oral medication group（16）and hypoglycemia group（16）.The oral medication rats and hypoglycemia rats were given glibenclamide＋metformin by intragastric administration once daily for 12 d,the dose of hypoglycemia rats was 5times of treatment rats.The brain tissues of rats in each group were used respectively the RT-PCR method to detect NGF mRNA at 3,6,9and 12 d.Results Compared with the control group,the expression of NGF mRNA in the brain tissues of the 3groups of diabetic rats were decreased in different degrees and the non-medication group was the most obvious（P〈0.01）.Compared with the non-medication group,the oral medication group was significantly increased（P〈0.01）,the hypoglycemia group was further decreased（P〈0.01）.Conclusion Oral hypoglycemic drugs can effectively enhance the expression of NGF mRNA in brain tissue of diabetic rats,but hypoglycemia caused by Oral antidiabetic drugs can make the expression of NGF mRNA further decreased.So hypoglycemia is not conducive to the repair of diabetic neuropathy.
出处
《重庆医学》
CAS
北大核心
2017年第8期1017-1019,共3页
Chongqing medicine
基金
四川省卫生厅科研课题(120478)
关键词
低血糖症
糖尿病
神经生长因子
口服降糖药
hypoglycemia
diabetes mellitus
nerve growth factor
oral hypoglycemic drugs
